

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate  
the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe  
Glabellar Lines

NCT Number: NCT03736928

SAP Document Date: 24Apr2019

# Statistical Analysis Plan

Clinical Trial Number: 43USD1801

## Table of Contents

<b>1 Study Information.....</b>	<b>4</b>
1.1 Background .....	4
1.1.1 Study Design .....	4
1.1.2 Number of Subjects and Randomization .....	4
1.2 Study Objectives .....	4
1.2.1 Primary Efficacy Objective.....	5
1.2.2 Secondary Efficacy Objectives .....	5
1.2.3 Safety Objectives .....	5
1.3 Efficacy Assessments.....	5
[REDACTED]	
1.4 Efficacy Endpoints .....	7
1.4.1 Primary Efficacy Endpoint.....	7
1.4.2 Secondary Efficacy Endpoints .....	7
1.5 Safety Assessments .....	9
1.6 Safety Endpoints .....	9
<b>2 Statistical Methods.....</b>	<b>11</b>
2.1 General Methods .....	11
2.1.1 Programming Conventions .....	11
2.1.2 Reporting Conventions .....	11
2.1.3 Data Transformations.....	12
2.2 Analysis Populations.....	12
2.2.1 Intent-to-treat Efficacy Population.....	12
2.2.2 Per-Protocol Efficacy Population.....	12
2.2.3 Safety Population .....	12
2.3 Study Subjects.....	12
2.3.1 Subject Disposition .....	12
2.3.2 Protocol Deviations.....	13
2.3.3 Demographic Characteristics .....	13

 GALDERMA	Title	Statistical Analysis Plan 43USD1801 - [REDACTED]	Doc id	[REDACTED]
2.3.4	Medical History, Medications, and Procedures .....	13		
2.4	Efficacy Analysis .....	13		
2.4.1	Datasets Analyzed.....	13		
2.4.2	Handling of Missing Data.....	14		
2.4.3	Primary Efficacy Analysis.....	14		
2.4.4	Secondary Analysis.....	14		
2.5	Safety Analysis .....	15		
2.5.1	Extent of Exposure.....	15		
2.5.2	Adverse Events .....	15		
2.5.3	Other Safety Assessments.....	15		
2.6	Data Safety Monitoring Committee Reviews .....	16		
2.6.1	Pre-Specified Stopping Criteria .....	16		
2.7	Interim Analyses .....	16		
2.8	Determination of Sample Size .....	17		
2.9	Changes in the Analysis Planned in the Protocol .....	17		
3	Reference List.....	18		

## 1 Study Information

## 1.1 Background

This statistical analysis plan (SAP) describes the analysis variables and statistical procedures that will be used to analyze and report the results from Protocol 43USD1801 (v1.0), dated 10 AUG 2018.

The SAP was written in accordance with the recommendations outlined in the International Conference on Harmonisation (ICH) E9 Guideline entitled “Guidance for Industry: Statistical Principles for Clinical Trials” and the ICH-E3 Guideline entitled “Guidance for Industry: Structure and Content of Clinical Study Reports”.

### 1.1.1 Study Design

This is a phase 2, multicenter, randomized, dose-ranging, double-blind, placebo-controlled, United States (US) study to assess the safety and efficacy of abobotulinumtoxinA for the treatment of moderate to severe glabellar lines.

After undergoing a screening visit, enrolled subjects will receive a single treatment of abobotulinumtoxinA or placebo at baseline. The planned clinical study duration (from first subject first visit to last subject last visit) is approximately 21.5 months.

### 1.1.2 Number of Subjects and Randomization

The study is planned to enroll approximately 400 subjects who will be treated with [REDACTED] abobotulinumtoxinA (approximately 80 subjects/dose) or placebo (up to 80 subjects depending on the number of dose groups that will run in the study).

Initially, eligible subjects will be randomly assigned at baseline to one of the following treatment

### 1.2.1 Primary Efficacy Objective

The primary efficacy objective is to evaluate a single dose of [REDACTED] abobotulinumtoxinA, respectively, compared to placebo in the treatment of moderate to severe glabellar lines using the Investigator Live Assessment (ILA) [REDACTED] Photographic Scale and the Subject Self-Assessment (SSA) Static [REDACTED] Categorical Scale at maximum frown at Month 1, concurrently.

### 1.2.2 Secondary Efficacy Objectives

- [REDACTED]

### 1.2.3 Safety Objectives

The safety objective is to evaluate the effect on safety endpoints of a single dose of [REDACTED] abobotulinumtoxinA compared to placebo in the treatment of glabellar lines.

## 1.3 Efficacy Assessments

For all assessments, baseline will be defined as the observation that is closest to but prior to study treatment on Day 0. Likewise, change from baseline will be calculated as the value at a given time point minus the baseline value.

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]



## 1.4 Efficacy Endpoints

### 1.4.1 Primary Efficacy Endpoint

The [REDACTED] responder rate will be evaluated using the ILA [REDACTED] Photographic Scale and the SSA Static 4-Point Categorical Scale of Glabellar Line Severity at maximum frown at Month 1. [REDACTED]

[REDACTED] improvement from baseline

### 1.4.2 Secondary Efficacy Endpoints

Effective date: 2019-04-24 19:40

*Effective*

Version: 2.0

## 1.5 Safety Assessments

The methods for collecting safety data are described in Section 7.2 of the Clinical Study Protocol.

## 1.6 Safety Endpoints

Safety endpoints include:

### (i) Treatment Emergent Adverse Events (TEAEs)

Adverse events (AEs) are to be monitored throughout the course of the study. The study period for the purpose of AE collection is defined as the period from the signing of a study specific informed consent to study exit for a subject. AEs recorded on the electronic case report forms (eCRFs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). AEs will be classified as treatment-emergent adverse events (TEAEs) if the AE had an onset time greater than or equal to the time of the dose of study treatment.

Adverse events endpoints include:

- Incidence,
- Causality (related/not related to investigational product),
- Intensity (mild/moderate/severe),
- Time to onset,
- Duration,
- Leading to study withdrawal,
- Seriousness.

### (ii) Neutralizing Antibody Production

[REDACTED]

**(iii) Laboratory Safety Tests**

Hematology and blood chemistry laboratory safety tests will be performed [REDACTED]

Laboratory safety test endpoints include:

- Values,
- Changes from baseline.

For each out of range laboratory result, the Investigator or designee will assess for clinical significance. All clinically significant out-of-range laboratory values for blood samples collected at baseline will be recorded in the medical history. All clinically significant out-of-range laboratory values for blood samples collected after baseline are to be reported as an AE if this abnormality was not present at the baseline visit or is assessed as having worsened since the baseline visit (i.e. there is a significant change from baseline). In instances when a laboratory abnormality is reported, the Investigator is to provide a diagnosis rather than reporting individual laboratory abnormalities, whenever possible.

**(iv) Focused Physical Examination**

Investigator or designee will perform a physical examination of the subject that includes the face and neck. The Investigator may choose to investigate any other sign that he/she observes during the physical examination and should assess all abnormal findings for clinical significance.

**(v) Vital Signs**

Vital signs (including blood pressure, heart rate, and respiratory rate) will be evaluated [REDACTED]

Vital signs endpoints include:

- Values,
- Changes from baseline.

All abnormal values at the screening visit identified as clinically significant by the Investigator will be recorded in the medical history.

For any clinically significant changes from the screening visit, an AE is to be recorded.

Normal ranges checks, as programmed in the eCRF to alert the investigator to assess clinical significance for values outside of these ranges, are shown in Table 4 below.

**Table 4. Vital Sign Normal Ranges**

Measure	Normal Range
Sitting Systolic blood pressure	90-150 mmHg
Sitting Diastolic blood pressure	60-90 mmHg
Sitting Heart rate	50-100 beats/min
Sitting Respiratory rate	12-24 breaths/min

## 2 Statistical Methods

### 2.1 General Methods

Any change made to the finalized SAP will be documented in the Clinical Study Report (CSR).

Some of the analyses detailed here may be more explicit or in some aspects different from those stated in the protocol. In case of differences, this SAP supersedes the statistical sections in the protocol.

#### 2.1.1 Programming Conventions

EMB Statistical Solutions will have responsibility for performing analyses. All computations for statistical analyses will be performed using SAS® software, Version 9.4 or later. All SAS programs used in the production of statistical summary outputs will be validated with independent programming prior to finalization. In addition, all program outputs will be independently reviewed. The validation process will be used to confirm that all data manipulations and calculations were accurately done. Once validation is complete, a senior statistical reviewer will perform a final review of the documents to ensure the accuracy and consistency with this plan and consistency within tables. Upon completion of validation and quality review procedures, all documentation will be collected and filed by the project statistician or designee.

The eCRF data for all subjects will be provided in Standard Data Tabulation Model (SDTM) datasets. Analysis Data Model (ADaM) datasets will be developed from the SDTM datasets for use in table and figure production.

#### 2.1.2 Reporting Conventions

The formats for the tables, listings, and figures described in this SAP will be provided in a companion document. Changes to the formats of these reports that are decided after the finalization of the SAP will not require an amendment. In addition, any additional supportive or exploratory analyses requested after SAP approval will not require amendment of the SAP. These additional analyses will be described in the CSR.

All study data from the eCRFs as well as derived variables will be provided in subject data listings. An indication of specific listings for each data type will not be indicated in the text of subsequent SAP sections. Data listings supplied as part of the CSR will be sorted by treatment group, study center number concatenated with subject number, assessment dates, and/or time point.

The following conventions will be applied to all data presentations and analyses:

- Placebo-treated subjects will be pooled together in summary tables and for analyses.
- Treatment groups to be summarized include [REDACTED] abobotulinumtoxinA and pooled placebo.
- Quantitative variables will generally be summarized by the number of subjects, mean, standard deviation, median, Q1, Q3, minimum, and maximum. Unless otherwise specified, the minimum and maximum values will be displayed to the same number of decimal places as the raw data, the mean and median will be presented to one extra decimal place compared to the raw data, and the standard deviation will be displayed to two extra decimal places compared to the raw data.

- Categorical variables will be summarized by the number and percentage of subjects within each category. Unless otherwise specified, the percentage will be presented in parentheses to one decimal place. Frequency and percentage values of 0 will be presented as '0' rather than '0 (0)'.
- All summary tables will include the analysis population sample size (i.e. number of subjects) in each treatment group.
- Date variables will be formatted as DDMMYY for presentation.

### 2.1.3 Data Transformations

[REDACTED]

[REDACTED]

## 2.2 Analysis Populations

The statistical analyses will be performed based on the following subject populations.

### 2.2.1 Intent-to-treat Efficacy Population

The Intent-to-treat (ITT) population includes all subjects who are randomized and dispensed (i.e., administered) the investigational product, and will be analyzed according to the randomization scheme. All primary efficacy, secondary efficacy, and exploratory variables will be analyzed based on the ITT population.

### 2.2.2 Per-Protocol Efficacy Population

The Per-Protocol (PP) population includes all ITT subjects who have no protocol deviations considered to have a substantial impact on the primary efficacy outcome, and will be analyzed according to the randomization scheme. If the PP population contains less than 90% of the subjects in the ITT, a sensitivity analysis of the primary efficacy endpoint will be performed based on the PP population.

### 2.2.3 Safety Population

The safety population includes all subjects who were administered the investigational product, and will be analyzed according to as-treated principle. All safety data will be summarized descriptively based on the safety population.

## 2.3 Study Subjects

### 2.3.1 Subject Disposition

The number of subjects screened will be shown in total and by study center.

The number of subjects in each study population (i.e. ITT, PP, and Safety) will be summarized by study center and in total (by treatment group and overall).

The disposition of subjects will be presented by treatment group, and in total, including numbers of subjects who were:

- Randomized,
- Completed,
- Withdrawn (including primary reason for withdrawal).

These numbers will also be presented by study center. The number of completed and withdrawn subjects will also be presented by visit.

### 2.3.2 Protocol Deviations

Subjects with any protocol deviations will be summarized by study center and in total (by treatment group and overall).

Depending on the seriousness of the deviation, a subject might be excluded from the PP population, which shall be documented prior to database lock. Since the PP population will be used for the primary analysis at Month 1 only, the focus will be on major deviations occurring before and on the Month 1 visit which are considered to have a substantial impact on the primary efficacy outcome. Reasons for exclusion from the PP population will be presented by treatment group and overall.

### 2.3.3 Demographic Characteristics

Subject demographic data will be summarized for the ITT population by treatment group and overall. Age and body mass index will be analyzed as continuous variables. Gender, race, ethnicity, Fitzpatrick skin type, childbearing potential, and toxin naïve status will be analyzed as categorical variables.

### 2.3.4 Medical History, Medications, and Procedures

All summaries will be done for the ITT population by treatment group and overall.

Prior and concomitant medications will be coded using the World Health Organization Drug Dictionary (WHODD). Medical history, allergen history (food, environmental, and drug), and prior and concomitant procedures/non-pharmacological treatments will be coded according to MedDRA.

Prior medications/procedures are the medications/procedures with stop dates prior to study treatment. Medications/procedures after the study treatment will be considered concomitant.

The number and percent of subjects reporting medical history, allergen history, cosmetic treatments/procedures, and prior and concomitant procedures/non-pharmacological treatments will be summarized by system organ class (SOC) and Preferred Term (PT).

The number and percent of subjects reporting prior and concomitant medications will be summarized separately, by WHODD Anatomical Therapeutic Chemical (ATC) Class Level 3 (if Level 3 is not available, will use the highest class available) and WHODD generic name.

## 2.4 Efficacy Analysis

### 2.4.1 Datasets Analyzed

All efficacy variables will be analyzed based on the ITT population. A sensitivity analysis of the primary efficacy endpoint will be performed based on the PP population. Summary statistics will be computed for each efficacy endpoint using the Observed Cases (OC) with no imputation for missing

data. Inferential statistical analyses will account for missing data as appropriate (SAP Section 2.4.2 below).

#### 2.4.2 Handling of Missing Data

The primary and secondary efficacy analyses will be performed using the baseline observation carried forward (BOCF), and the analysis of the primary endpoint will be repeated using multiple imputation (MI) for missing values. If deemed necessary, any analyses may be repeated using OC, BOCF, or MI as appropriate.

##### Multiple Imputation

The imputation using MI will assume Missing Completely at Random (MAR). The MI procedure of the SAS® system will be used to generate five sets of data with missing values imputed from observed data. It is expected that the pattern of missing data will be monotonic, with slight deviations being corrected by the Markov Chain Monte Carlo (MCMC) method of the MI procedure. Linear regression will be employed to model the missing ILA and SSA scores, with the following covariates included in the imputation model: treatment and non-missing data from earlier visits than Month 1. The imputed datasets will be analyzed using the methodology described for the primary analysis. The results from the analysis of the multiple imputed datasets will be combined by the MIANALYZE procedure of the SAS® system.

#### 2.4.3 Primary Efficacy Analysis

The Month 1 responder rates of abobotulinumtoxinA will be compared with placebo

#### 2.4.4 Secondary Analysis

## 2.5 Safety Analysis

All safety data will be summarized descriptively by treatment group based on the safety population using the Observed Cases (OC). There are no planned inferential statistical analyses of safety endpoints.

### 2.5.1 Extent of Exposure

Because subjects will receive a single dose of investigational product, no summary of extent of exposure will be performed. Extent of exposure will be provided in a subject data listing.

### 2.5.2 Adverse Events

An overall summary of all AEs will be provided by treatment group, which will include:

- number and percentage of subjects with at least one AE and number of events,
- number and percentage of subjects with at least one TEAE and number of events,
- number and percentage of subjects with at least one treatment-related TEAE and number of events,
- number and percentage of subjects with at least one mild, moderate, and severe TEAE and number of events,
- number and percentage of subjects with at least one TEAE leading to discontinuation and number of events,
- number and percentage of subjects with at least one serious TEAE and number of events.

All TEAEs, serious TEAEs, TEAEs by maximum intensity, TEAEs by causality, TEAEs by maximum intensity and causality, treatment-related TEAEs, and TEAEs leading to discontinuation will be summarized by treatment group, SOC, and PT including number of subjects with at least one event, percentages, and number of events.

For treatment-related AEs, the number of days to onset and duration of event will be summarized by treatment group, SOC, and PT.

Time to onset of an AE will be derived as the start date minus the date of treatment. If the start date is missing, it will be assumed that the AE started on the day of treatment.

Duration of an AE will be derived as the stop date minus the start date + 1. If the start date is missing, it will be assumed that the AE started on the day of treatment. Missing stop date will not be imputed and therefore no duration will be calculated in these cases.

For subject counts, a subject will only be counted once per SOC and once per PT in cases where multiple events are reported for a subject within SOC or PT. For event counts, subjects with multiple events in a category will be counted for each event.

### 2.5.3 Other Safety Assessments

Data for hematology, blood chemistry, [REDACTED] and vital signs will be summarized by treatment group using descriptive statistics with the value at each visit as well as the change from baseline. The numbers and percentages of subjects with abnormalities in focused physical examination will also be summarized by treatment group. The results of the urine pregnancy tests will only be listed.

## 2.6 Data Safety Monitoring Committee Reviews

There will be two reviews by an unblinded independent Data Safety Monitoring Committee (DSMC) during the study. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

### 2.6.1 Pre-Specified Stopping Criteria

The DSMC reviews will be based on tables of summary statistics and listings. No statistical inference will be performed.

Evaluation of safety data will include application of the following stopping criteria:

- [REDACTED]
- [REDACTED]
- [REDACTED]

Further, the DSMC will review the list of AEs (including confirmed AEs of local or remote spread of toxin) and advise the Sponsor of safety findings that may result in discontinuation of study enrollment.

## 2.7 Interim Analyses

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

## 2.8 Determination of Sample Size

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Thus, a sample size of 80 in each group is planned to be sufficient to explore the safety and responder rates over time.

[REDACTED]

[REDACTED]

### **3 Reference List**

There are no other references beyond those that are included in the protocol.

## *Effective*

2019-04-24 19:40

Effective date:



Version: 2.0

Page 19 of 20

*Effective*

Version: 2.0

Effective date: 2019-04-24 19:40

 GALDERMA	Title Statistical Analysis Plan 43USD1801 - 	Doc id 
		

# *Effective*

2019-04-24 19:40

Effective date:

Version: 2.0



Title  
Statistical Analysis Plan 43USD1801 - [REDACTED]

Doc id  
[REDACTED]